Description
Feline Diabetes – Thinking Outside the Bottle
Even though diabetes in cats isn’t new, some of the options for treating diabetic cats are. How do you know when to use insulin, or when it’s ok to choose a sodium-glucose cotransporter2 (SGLT2) inhibitor? After a quick review of the unique characteristics of feline diabetes mellitus and the associated risk factors, the course will examine this new class of drugs of SGLT2 inhibitors, and how the new treatment exerts its action in the kidneys to increase excretion of glucose in the urine and lower blood glucose levels. The course will cover safety and effectiveness results and answer how to make the best treatment decisions to dramatically improve life for diabetic cats, their caregivers, and veterinarians.
WEBINAR OBJECTIVES
After attending this webinar, participants should be able to:
- Be comfortable in identifying which cats are appropriate for treatment with an SGLT2 inhibitor.
- Understand the key points of monitoring cats who are on SGLT2 inhibitors.
- Get tools to communicate with clients and staff about the safety and efficacy of this new class of treatment for diabetic cats.
This course has been certified by or provided by the following Certified Organization/s:
• AAVSB-Registry of Approved Continuing Education (RACE) - 1.00 Hours
• New York State Board of Veterinary Medical Examiners - 1.00 Hours
US-PET-0350-2024
Important Safety InformationCats treated with Senvelgo® may be at an increased risk of diabetic ketoacidosis or euglycemic ketoacidosis. As diabetic ketoacidosis and euglycemic ketoacidosis in cats treated with SENVELGO may result in death, development of these conditions should be treated promptly, including insulin administration and discontinuation of SENVELGO. Due to the risk of developing diabetic ketoacidosis or euglycemic ketoacidosis, do not use SENVELGO in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. SENVELGO should not be initiated in cats with anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus or without appropriate screening tests.
SENVELGO® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2024 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved.